Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1;14(3):e0213219.
doi: 10.1371/journal.pone.0213219. eCollection 2019.

Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort

Ana Paula Monteiro Gomides  1   2 , Cleandro Pires de Albuquerque  1 , Ana Beatriz Vargas Santos  3 , Rodrigo Balbino Chaves Amorim  3 , Manoel Barros Bértolo  4 , Paulo Louzada Júnior  5 , Isabela Araújo Santos  5 , Rina Dalva Neubarth Giorgi  6 , Nathalia de Carvalho Sacilotto  6 , Sebastião Cezar Radominski  7 , Fernanda Maria Borghi  8 , Maria Fernanda B Resende Guimarães  9 , Maria Raquel da Costa Pinto  9 , Gustavo Gomes Resende  9 , Karina Rossi Bonfiglioli  10 , Henrique Carriço da Silva  10 , Maria de Fátima Lobato da Cunha Sauma  11 , Marcel Lobato Sauma  11 , Júlia Brito de Medeiros  11 , Ivânio Alves Pereira  12 , Gláucio Ricardo Wernwer de Castro  13 , Claiton Viegas Brenol  14 , Ricardo Machado Xavier  14 , Licia Maria Henrique da Mota  1 , Geraldo da Rocha Castelar Pinheiro  3
Affiliations

Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort

Ana Paula Monteiro Gomides et al. PLoS One. .

Erratum in

Abstract

The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.

PubMed Disclaimer

Conflict of interest statement

Ana Paula Monteiro Gomides: Has received personal support and consulting fees from Pfizer. Cleandro Pires de Albuquerque: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB Ana Beatriz Vargas Santos: Has received supporting for international medical events from AbbVie and Janssen Rodrigo Balbino Chaves Amorim: No financial disclosures Manoel Barros Bértolo: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer Paulo Louzada Júnior: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer Isabela Araújo Santos: No financial disclosures Rina Dalva Neubarth Giorgi: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS Sebastião Cezar Radominski: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB Fernanda Maria Borghi: No financial disclosures Maria Fernanda B. Resende Guimarães: No financial disclosures Karina Rossi Bonfiglioli: Has received speaking fees and supporting for international congresses from Roche, Pfizer, Bristol-Myers Squibb, Abbvie and Janssen. Henrique Carriço da Silva: No financial disclosures Maria de Fátima Lobato da Cunha Sauma: No financial disclosures Ivânio Alves Pereira: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen Gláucio Ricardo Wernwer de Castro: No financial disclosures Claiton Viegas Brenol: Has participated in clinical and/or experimental studies related to this work and sponsored by AbbVie, BMS, Janssen, Pfizer and Roche; has received personal or institutional support from AbbVie, BMS, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer and Roche Ricardo Machado Xavier: Consultancies for Abbvie, BMS, GSK, Janssen, Lilly, Novartis, Pfizer, Roche, UCB. Clinical trials: Abbvie, UCB, Pfizer, GSK, Lilly. Licia Maria Henrique da Mota: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB. Geraldo da Rocha Castelar Pinheiro: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

References

    1. Kahlenberg JM, Fox DA. Advances in the medical treatment of rheumatoid arthritis. Hand Clin. 2011; 27:11–20. 10.1016/j.hcl.2010.09.002 - DOI - PMC - PubMed
    1. Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017; 4:247–261. 10.1007/s40744-017-0073-3 - DOI - PMC - PubMed
    1. Mota LMH, Kakehasi AM, Gomides APM, Duarte ALBP, Cruz BA, Brenol CV et al. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Adv Rheumatol. 2018; 58:2 10.1186/s42358-018-0005-0 - DOI - PubMed
    1. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases. 2017;76:960–977. 10.1136/annrheumdis-2016-210715 - DOI - PubMed
    1. Singh JA, Saag K G, Bridges SL, Akl EA, Bannuru RR, Sullivan MC et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2016; 68: 1–25. 10.1002/acr.22783 - DOI - PubMed

Publication types

MeSH terms